72 related articles for article (PubMed ID: 3607783)
1. Scheduling of vincristine: drug accumulation and response of xenografts of childhood rhabdomyosarcoma determined by frequency of administration.
Houghton JA; Meyer WH; Houghton PJ
Cancer Treat Rep; 1987; 71(7-8):717-21. PubMed ID: 3607783
[TBL] [Abstract][Full Text] [Related]
2. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
[TBL] [Abstract][Full Text] [Related]
3. Determinants of intrinsic sensitivity to Vinca alkaloids in xenografts of pediatric rhabdomyosarcomas.
Houghton JA; Williams LG; Torrance PM; Houghton PJ
Cancer Res; 1984 Feb; 44(2):582-90. PubMed ID: 6692363
[TBL] [Abstract][Full Text] [Related]
4. Stability of vincristine complexes in cytosols derived from xenografts of human rhabdomyosarcoma and normal tissues of the mouse.
Houghton JA; Williams LG; Houghton PJ
Cancer Res; 1985 Aug; 45(8):3761-7. PubMed ID: 2990677
[TBL] [Abstract][Full Text] [Related]
5. In situ selection of a human rhabdomyosarcoma resistant to vincristine with altered beta-tubulins.
Houghton JA; Houghton PJ; Hazelton BJ; Douglass EC
Cancer Res; 1985 Jun; 45(6):2706-12. PubMed ID: 3986804
[TBL] [Abstract][Full Text] [Related]
6. Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays.
Pawlik CA; Houghton PJ; Stewart CF; Cheshire PJ; Richmond LB; Danks MK
Clin Cancer Res; 1998 Aug; 4(8):1995-2002. PubMed ID: 9717830
[TBL] [Abstract][Full Text] [Related]
7. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
[TBL] [Abstract][Full Text] [Related]
8. Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts.
Horton JK; Thimmaiah KN; Houghton JA; Horowitz ME; Houghton PJ
Biochem Pharmacol; 1989 Jun; 38(11):1727-36. PubMed ID: 2735930
[TBL] [Abstract][Full Text] [Related]
9. The pediatric preclinical testing program: description of models and early testing results.
Houghton PJ; Morton CL; Tucker C; Payne D; Favours E; Cole C; Gorlick R; Kolb EA; Zhang W; Lock R; Carol H; Tajbakhsh M; Reynolds CP; Maris JM; Courtright J; Keir ST; Friedman HS; Stopford C; Zeidner J; Wu J; Liu T; Billups CA; Khan J; Ansher S; Zhang J; Smith MA
Pediatr Blood Cancer; 2007 Dec; 49(7):928-40. PubMed ID: 17066459
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice.
Houghton JA; Houghton PJ; Green AA
Cancer Res; 1982 Feb; 42(2):535-9. PubMed ID: 7034923
[TBL] [Abstract][Full Text] [Related]
11. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
12. Prolonged circulation and increased tumor accumulation of liposomal vincristine in a mouse model of rhabdomyosarcoma.
Roveri M; Pfohl A; Jaaks P; Alijaj N; Leroux JC; Luciani P; Bernasconi M
Nanomedicine (Lond); 2017 May; 12(10):1135-1151. PubMed ID: 28447920
[TBL] [Abstract][Full Text] [Related]
13. Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma.
Houghton JA; Cook RL; Lutz PJ; Houghton PJ
Cancer Treat Rep; 1985 Jan; 69(1):91-6. PubMed ID: 3967262
[TBL] [Abstract][Full Text] [Related]
14. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma.
Cinatl J; Cinatl J; Michaelis M; Kabickova H; Kotchetkov R; Vogel JU; Doerr HW; Klingebiel T; Driever PH
Cancer Res; 2003 Apr; 63(7):1508-14. PubMed ID: 12670897
[TBL] [Abstract][Full Text] [Related]
15. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
[TBL] [Abstract][Full Text] [Related]
16. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
Meza JL; Anderson J; Pappo AS; Meyer WH;
J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
[TBL] [Abstract][Full Text] [Related]
17. Development of resistance to vincristine in a childhood rhabdomyosarcoma growing in immune-deprived mice.
Houghton JA; Houghton PJ; Brodeur GM; Green AA
Int J Cancer; 1981 Oct; 28(4):409-15. PubMed ID: 7309287
[TBL] [Abstract][Full Text] [Related]
18. Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors.
Kellie SJ; Koopmans P; Earl J; Nath C; Roebuck D; Uges DR; De Graaf SS
Cancer; 2004 Jun; 100(12):2637-43. PubMed ID: 15197807
[TBL] [Abstract][Full Text] [Related]
19. Relationship between binding affinity, retention and sensitivity of human rhabdomyosarcoma xenografts to Vinca alkaloids.
Houghton JA; Williams LG; Dodge RK; George SL; Hazelton BJ; Houghton PJ
Biochem Pharmacol; 1987 Jan; 36(1):81-8. PubMed ID: 3541941
[TBL] [Abstract][Full Text] [Related]
20. STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model.
Gao L; Chen L; Fei XH; Qiu HY; Zhou H; Wang JM
Chin Med J (Engl); 2006 Jun; 119(11):911-8. PubMed ID: 16780770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
